Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (161-170 of 226) with videos related to

Pageof 23
Sort By:
Autophagy|May 11, 2016
Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophagesJacinta P W Lee, Andrew Foote, Huapeng Fan, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.
Nature Communications|April 28, 2015
Manipulation of B-cell responses with histone deacetylase inhibitorsMichaela Waibel, Ailsa J Christiansen, Margaret L Hibbs, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
The Lancet. Rheumatology|January 27, 2024
The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosusChi Chiu Mok, Laniyati Hamijoyo, Nuntana Kasitanon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2013
GILZ overexpression inhibits endothelial cell adhesive function through regulation of NF-κB and MAPK activityQiang Cheng, Huapeng Fan, Devi Ngo, et al.
The Lancet. Rheumatology|May 10, 2026
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trialEric F Morand, Victoria P Werth, Joerg Wenzel, et al.
Theranostics|January 19, 2018
Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell InterplayPatricia Luz-Crawford, Gabriel Espinosa-Carrasco, Natacha Ipseiz, et al.
Pageof 23

Showing results (161-170 of 226) with videos related to

Sort By:
Pageof 23
Autophagy|May 11, 2016
Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophagesJacinta P W Lee, Andrew Foote, Huapeng Fan, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.
Nature Communications|April 28, 2015
Manipulation of B-cell responses with histone deacetylase inhibitorsMichaela Waibel, Ailsa J Christiansen, Margaret L Hibbs, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
The Lancet. Rheumatology|January 27, 2024
The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosusChi Chiu Mok, Laniyati Hamijoyo, Nuntana Kasitanon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2013
GILZ overexpression inhibits endothelial cell adhesive function through regulation of NF-κB and MAPK activityQiang Cheng, Huapeng Fan, Devi Ngo, et al.
The Lancet. Rheumatology|May 10, 2026
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trialEric F Morand, Victoria P Werth, Joerg Wenzel, et al.
Theranostics|January 19, 2018
Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell InterplayPatricia Luz-Crawford, Gabriel Espinosa-Carrasco, Natacha Ipseiz, et al.
Pageof 23